Compare · NVO vs RNTX
NVO vs RNTX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rein Therapeutics Inc. (RNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 3205.6x RNTX ($54.2M).
- NVO has hit the wire 4 times in the past 4 weeks while RNTX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 2 for RNTX).
- Company
- Novo Nordisk A/S
- Rein Therapeutics Inc.
- Price
- -
- -
- Market cap
- $173.66B
- $54.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest RNTX
- Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
- Rein Therapeutics to Present at Upcoming September Investor Conferences
- Rein Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
- Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Rein Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Rein Therapeutics Inc.
- Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
- SEC Form 8-K filed by Rein Therapeutics Inc.
- Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries